Search Results 161-170 of 17276 for hba1c

  1. Statins For The Treatment Of NASH - Mayo Clinic

    HbA1C > 9.0 %; 2. Neutrophil count < 1.0 x 10^9 / L; 3. Platelets < 100 10^9 / L; 4. Hemoglobin < 10 g/dl; 5. Albumin < 3.5 g; 6. Prolonged international ...

  2. Fuchs Clinical Trials - Mayo Clinic Research

    ... (HbA1c), and skin advanced glycation endproducts (AGE) and ... . Mayo Clinic Footer. Request Appointment · Give Now · Contact Us · About Mayo Clinic · Employees ...

  3. Phase III Copanlisib In Rituximab-refractory INHL - Mayo Clinic

    Type I or II diabetes mellitus with HbA1c > 8.5% at Screening. Known history of human immunodeficiency virus (HIV) infection. Active clinically serious ...

  4. A Study Of ATR-101 For The Treatment Of Cushing’s Syndrome - Mayo Clinic

    Uncontrolled diabetes mellitus, as evidenced by HbA1c > 9.0% at screening; Uncontrolled hypertension, defined as systolic blood pressure > 160 mmHg or ...

  5. A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease - Mayo Clinic

    The participant has a serum glycosylated hemoglobin (HbA1c) less than 9.5% at the Screening Visit. 5. The participant has a documented clinical diagnosis of ...

  6. Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension - Mayo Clinic

    Uncontrolled diabetes mellitus (HbA1c >9%) within 3 months of screening; Significant systemic or major illness other than liver disease; HIV infection; Use of ...

  7. Islet GLP-1 in Prediabetes - Clinical Trials

    HbA1c ³ 6.5%; Use of any glucose-lowering agents including metformin or sulfonylureas. For female subjects: positive pregnancy test at the time of enrollment ...

  8. Publications - Aoife M. Egan, M.B., B.Ch., Ph.D. - Mayo Clinic

    ... HbA1c but increase diabetic ketoacidosis. Ann Intern Med. 2018 Jul 17; 169 (2):JC3 View PubMed; Chambers SEJ, O'Neill CL, Guduric-Fuchs J, McLoughlin KJ ...

  9. Study Evaluating The Safety, Tolerability, And Effectiveness Of EDP-305 In Subjects With Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

    ... HbA1c of at least 6% with or without concomitant treatment with metformin. AND. Screening MRI-PDFF with >8% steatosis;; Body mass index (BMI) >25 kg/m2. NOTE ...

  10. A Study To Evaluate The Safety And Effectiveness Of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant As Treatment For Locally Advanced (Inoperable) Or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer - Mayo Clinic

    HbA1c ≥ 8.0% (63.9 mmol/mol). Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular ...